2002
DOI: 10.1159/000069709
|View full text |Cite
|
Sign up to set email alerts
|

Simulated in vitro Quinolone Pharmacodynamics at Clinically Achievable AUC/MIC Ratios: Advantage of <i>I</i><sub>E</sub> over Other Integral Parameters

Abstract: To compare the antimicrobial effects of clinically achievable ratios of area under the curve (AUC) to MIC, a clinical isolate of Moraxella catarrhalis was selected with MICs corresponding to the MIC50s of four quinolones. Monoexponentially declining concentrations observed in human plasma after oral administration of 1,000 mg of ciprofloxacin (as two 500-mg doses at a 12-hour interval), 320 mg gemifloxacin, 500 mg levofloxacin or 400 mg moxifloxacin (each as a single dose) and were simulated in an i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
5
0

Year Published

2007
2007
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(6 citation statements)
references
References 10 publications
1
5
0
Order By: Relevance
“…However, 24 injections of free streptomycin could be replaced with 8 oral doses of PLG nanoparticle-encapsulated streptomycin. Furthermore, intramuscular free streptomycin resulted in nephrotoxicity (assessed on a biochemical basis), as reported earlier [19] , whereas oral PLG nanoparticle-encapsulated streptomycin did not elicit any adverse effects. This was possibly due to increased accumulation of intramuscular free streptomycin in the kidneys ( table 1 ), while encapsulation in PLG served to circumvent this problem ( table 1 ).…”
Section: Discussionsupporting
confidence: 79%
“…However, 24 injections of free streptomycin could be replaced with 8 oral doses of PLG nanoparticle-encapsulated streptomycin. Furthermore, intramuscular free streptomycin resulted in nephrotoxicity (assessed on a biochemical basis), as reported earlier [19] , whereas oral PLG nanoparticle-encapsulated streptomycin did not elicit any adverse effects. This was possibly due to increased accumulation of intramuscular free streptomycin in the kidneys ( table 1 ), while encapsulation in PLG served to circumvent this problem ( table 1 ).…”
Section: Discussionsupporting
confidence: 79%
“…Based on the time-kill data, the intensity of the antimicrobial effect (I E , defined as the area between the control-growth and time-kill curves; Firsov et al, 2002) was determined from time zero to the time when the effect could no longer be detected, i.e. the time after the last fluoroquinolone dose at which the number of antibiotic-exposed bacteria reached 10 9 c.f.u.…”
mentioning
confidence: 99%
“…Similarly, an in vitro dynamic model simulated human plasma levels after single oral doses of 1000 mg of ciprofl oxacin, 320 mg gemifl oxacin, 500 mg levofl oxacin or 400 mg moxifl oxacin against one isolate of Moraxella catarrhalis . Using traditional dosing interval-dependent endpoint, the time-kill/ regrowth curves demonstrated similar patterns with all study agents, while effect of moxifl oxacin as expressed by the I E was 30, 55, and 120 % greater than gemifl oxacin, levofl oxacin, and ciprofl oxacin, respectively [ 44 ].…”
Section: In Vitro Simulationsmentioning
confidence: 79%
“…Ultimately, the intensity of antimicrobial effect ( I E ) was shown to be an accurate descriptor endpoint of fl uoroquinolones antibacterial activity [ 39 -42 ]. Defi ned as the area between the control growth in the absence of antibiotics and the antibiotic-induced time-kill/regrowth curves [ 43 ], I E describes the area between the control and time-kill curves from time zero to the time when bacterial counts with antibiotic exposure reach the same maximal numbers as in the absence of antibiotic; which typically exceeds the dosing interval of a given agent [ 44 ]. This approach overcomes the limitations of traditional endpoints such as area between the control growth and time-kill curves and area under the time-kill curve, which describe the antimicrobial effects over a prespecifi ed dosing interval without regard to the actual duration of effect.…”
Section: In Vitro Simulationsmentioning
confidence: 99%